Mustang Bio Inc. is at the forefront of developing innovative cell and gene therapies aimed at treating hematologic cancers, glioblastoma, and rare genetic diseases. The company focuses on harnessing the potential of CAR T-cell therapies, particularly through its clinical programs such as MB-106, which targets B-cell Non-Hodgkin Lymphoma using a fully human antibody optimized for enhanced efficacy. Additionally, Mustang Bio is advancing therapies for glioblastoma with MB-101, which targets the IL-13Rα2 receptor, a marker present in a significant majority of GBM patients. The company’s commitment to translating scientific breakthroughs into viable treatments is evident in its robust pipeline and ongoing clinical trials.

In addition to CAR T-cell therapies, Mustang Bio is exploring the use of oncolytic viruses, specifically the C134 oncolytic herpes simplex virus (oHSV), which selectively replicates in tumor cells while sparing normal cells. This innovative approach not only aims to directly kill tumor cells but also utilizes the tumor environment to produce new viral particles, enhancing the therapeutic effect. The combination therapy MB-109 merges CAR T-cell therapy with the oncolytic virus to potentially transform "cold" glioblastoma tumors into "hot" tumors, thereby improving the effectiveness of the CAR T-cell treatment. This pioneering work positions Mustang Bio as a leader in the development of next-generation therapies that could significantly improve patient outcomes in oncology.

United States

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase 1/2 clinical trials. 

Cancer

Genetic Diseases

Hematologic Diseases

Rare diseases

Mustang Bio Inc

X-Linked severe combined immunodeficiency

MB-107 is a novel lentiviral gene therapy intended for the treatment of X-linked severe combined immunodeficiency (XSCID).
CAR T
Gene therapy

MB-107 

Myelofibrosis

MB-207

Chronic lymphocytic leukemia

Lymphoma

Non-Hodgkin lymphoma

MB 106 is a third generation fully human CD20 targeted CAR T cell therapy for treatment of NHL &amp; CLL. CD20 is a &nbsp;membrane-embedded surface molecule which plays a role in the &nbsp;differentiation of B-cells into plasma cells. &nbsp;
CAR T

MB-106 (CD20)  (Mustang Multicenter)

Epstein-Barr virus

Multiple sclerosis

Waldenstrom macroglobulinemia

MB-106 (CD20) (Fred Hutch)

Ependymoma

Glioblastoma

Leptomeningeal brain tumors

Medulloblastoma

IL13Rα2 is an attractive target for CAR T therapy as it has limited expression in normal tissue but is over‐expressed on the surface of the majority of GBM cells. CAR T cells are designed to express a membrane‐tethered IL‐13 receptor ligand (IL‐13) incorporating a single‐point mutation that provides high affinity for IL13Rα2 and reduces binding to IL13Rα1 in order to reduce healthy tissue targeting. MB‐101 as an optimized CAR T product incorporating enhancements in CAR design and T cell engineering to improve antitumor potency and T cell persistence.
CAR T

MB-101 (IL-13Ra2) + MB-108

Acute myeloid leukemia

Blastic plasmacytoid dendritic cell neoplasm

High risk myelodysplastic syndromes

MB-102 is a &nbsp;CAR T cell therapy that is produced by engineering patient T cells to &nbsp;recognize and eliminate CD123-expressing tumors. CD123 is widely &nbsp;expressed on bone marrow cells of patients with myelodysplastic &nbsp;syndromes, as well as in hematologic malignancies, including AML, and &nbsp;BPDCN.
CAR T

MB-102 (CD123)

Metastatic breast cancer to brain

MB-103 are autologous HER2-specific CAR-modified virus-specific T cells &nbsp;(VSTs). There were an estimated 12,760 new cases worldwide in 2018 with &nbsp;an estimated 30% 2-year survival rate. MB-103 has been fully optimized &nbsp;as a fully human HER2 CAR T and is currently in clinical studies at City &nbsp;of Hope.
CAR T

MB-103 (HER2)

Multiple myeloma

Solid tumor/s

MB-104 is a novel second-generation CS1-specific chimeric antigen receptor (CAR) T cell therapy for multiple myeloma (MM).
CAR T

MB-104

Prostate cancer

MB-105 was developed in the laboratory of Saul Priceman, Ph.D., &nbsp;assistant professor in City of Hope’s Department of Hematology &amp; &nbsp;Hematopoietic Cell Transplantation and associate director of &nbsp;translational sciences in the T Cell Therapeutics Research Laboratory &nbsp;led by Stephen Forman, M.D., Director of City of Hope’s Hematologic &nbsp;Malignancies Research Institute and the Laboratory’s Director.
The &nbsp;Phase 1 clinical trial of MB-105 will continue to enroll up to 33 &nbsp;patients. Its primary endpoints are to define safety and optimal dosing &nbsp;of PSCA CAR T cells in treating patients with PSCA-positive mCRPC. &nbsp;Secondary endpoints include assessing the expansion and persistence of &nbsp;PSCA CAR T cells, the clinical response based on Prostate Cancer Working &nbsp;Group 3 (PCWG3) criteria, survival outcomes and serum cytokine profiles &nbsp;in peripheral blood pre- and post-therapy, as well as describing the &nbsp;PSCA expression level on tumor cells prior to CAR T cell infusion and &nbsp;the relationship it may have with disease response and associated &nbsp;toxicities. For more information on this Phase 1 trial, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=jK6FYu-_pozHTAGR8fT059OrYPyM1fQaU-h0qqW1XENdCeizvgtu9tfoqpYElucywAi_mLUkGM6YWjuEcaAaWgNs5jwszda30auVVSRwAYcv0qEtx7LHCzuZ2eNDqYIFP4sRaOQtqSX8eh6vp2OgNjtkBc6um4aG4jnsw8boMA8LwsS6YaF06XQciwWKmYoqRAwMq5CxkvxQx266JDNXJ5Eey2nORv_7kbfccLuFrmOdpiYr_cxF0kyUutAbHx_qP9tBeXUamCgJl8p1d_YNkw==" rel="nofollow noopener" target="_blank" title="Opens in a new window">www.clinicaltrials.gov</a>&nbsp;using identifier&nbsp;<a href="https://www.globenewswire.com/Tracker?data=PwqQd2iFmYF5qh6ejE_79PYPs-tAPJHigTpCkmDIMZ9Rss6KAWnYV84ZcirM8YvWSWQdKDjTR_zvjkkSUx6-pFmGYmr5qgIkiw6SCPHtgQRT8RFR7c14jUk1AFdQ25XuZydwx97jUzkFyEa12WyOl5si7T_AS2UAR7P1ixyzlUI4DSCbkMyEJwkeWRkgjXdDW_ocHrMZZClXwFNI5lb53AH1JzOuYpkGQ8vqiaWfks3vmjdGAIHA8AaCgPUu_xRIgELIHgsgeIK8W2I_R6D0a_uKG9UtpVVle1W1XDnnQSE0u_NpOMhzgrsmzgko11CzXiCgbgmw64Bh9zAUgfh9RH5DSpg_kd8ySzDnki6tKOE=" rel="nofollow noopener" target="_blank" title="Opens in a new window">NCT03873805</a>.
CAR T

Mustang Bio Inc

Company Details